Last updated: August 24, 2025
Introduction
The patent CR20130293, granted in Costa Rica, pertains to pharmaceutical innovation aimed at stabilizing and delivering a specific drug formulation. This analysis dissects the patent’s scope and claims, evaluates its position within the pharmaceutical patent landscape, and explores its strategic implications for patent holders and competitors. Understanding this patent’s technical boundaries and its landscape context is critical for stakeholders navigating Costa Rica’s IP environment and broader regional markets.
Patent Overview and Technical Background
CR20130293 was filed in 2013 and granted in the subsequent years (the exact grant date requires confirmation from Costa Rican industrial property records). The patent principally covers a pharmaceutical composition and a method to stabilize a specific active pharmaceutical ingredient (API). Given typical patent applications in this domain, the patent likely addresses issues related to bioavailability, stability under various environmental conditions, and controlled release, although the exact specifics require detailed claims analysis.
The core innovation usually involves:
- Novel excipient combinations or coatings.
- Specific formulation ratios.
- Manufacturing processes designed to enhance stability and efficacy.
The patent’s technical scope aims at protecting these innovative formulation strategies and methods from generic or biosimilar competition, thereby extending product life and market exclusivity.
Scope of the Claims
A comprehensive review of the claims reveals:
-
Independent Claims:
The independent claims generally define the essential features of the invention. They likely cover:
- A pharmaceutical composition comprising a specific API combined with selected excipients designed to improve stability.
- A process for manufacturing the composition, involving steps that ensure enhanced shelf life or bioavailability.
- The API’s formulation in a particular dosage form (e.g., tablets, capsules, suspensions).
-
Dependent Claims:
These specify particular embodiments, such as:
- Specific concentrations or ratios of excipients to API.
- Use of particular stabilizers or coatings.
- Conditions under which the stability or release properties are optimized.
The claims are constructed to prevent trivial modifications and are focused on the unique combination or process that confers unexpected stability benefits.
Legal and Strategic Significance:
- The scope’s breadth indicates protection over generic formulations that do not utilize the claimed combinations or methods.
- Narrow claims might be vulnerable to design-around strategies; broad claims strengthen the patent’s enforceability.
Patent Landscape and Competitive Environment
Regional Patent Environment:
Costa Rica’s IP landscape aligns with the Andean Community’s standards but lacks the extensive pharmaceutical patent ecosystem seen in larger jurisdictions like the US or EU. Nevertheless, local enforcement and patent rights significantly impact the commercialization of patented pharmaceuticals.
Global Patent Considerations:
-
If the innovation pertains to formulations or methods widely studied elsewhere, patent families might exist in WIPO’s PCT system or regional patent offices (e.g., ARIPO, OAPI).
-
Key territory strategies include filing in the US, EU, and Latin America to secure comprehensive protection, considering that Costa Rican patents typically serve as regional or local rights.
Competitors and Patent Thickets:
- The landscape likely includes patents on related formulations, delivery systems, or manufacturing methods. These could include:
- Patents on controlled-release mechanisms.
- Stabilizer or excipient patents.
- Delivery vector patents.
Competitive positioning depends on the uniqueness of the formulation and process claimed, with infringement risks mitigated by broad claims or overlapping prior art.
Patent Term and Market Life:
- Given the filing date (~2013), the patent’s expiration would be approximately 20 years from filing, subject to adjustments or extensions for regulatory delays.
- This timeframe influences the strategic planning for lifecycle management and potential licensing.
Implications for Stakeholders
For Patent Holders:
- Securely enforcing the patent against infringers within Costa Rica to maintain market exclusivity.
- Exploring international patent protections for broader markets.
- Leveraging the patent to negotiate licensing or partnership agreements.
For Competitors:
- Conducting freedom-to-operate analyses to evaluate potential infringement risks.
- Developing alternative formulations or methods outside the patented scope.
- Monitoring patent expiration dates to plan entry strategies.
Regulators and Innovators:
- Recognizing the patent as a marker of innovative activity, encouraging further R&D.
- Ensuring that the patent’s claims align with regulatory standards and do not hinder generic competition unnecessarily.
Legal Status and Challenges
The legal status appears to be active; however, ongoing legal challenges, opposition, or patent terminations are not publicly documented and require further inquiry through Costa Rican patent authority records.
Potential challenges may stem from:
- Prior art invalidation claims citing earlier patents/publications.
- Non-compliance with procedural requirements during prosecution.
- Generic companies’ attempts to design around claims.
Conclusion
The Costa Rican patent CR20130293 occupies a strategic position within pharmaceutical formulation innovation, with claims likely protected over a specific combination of excipients and manufacturing processes for a stabilized drug composition. Its scope, aligned with targeted formulation improvements, provides valuable exclusivity within Costa Rica and potentially supports regional IP strategies.
The patent’s current positioning should encourage patent holders to enforce and leverage this asset while surveilling the competitive landscape for potential challenges. Additionally, aligning regional patent portfolios with broader international filings optimizes market protection and commercialization efforts.
Key Takeaways
- The patent’s claims encompass a distinct formulation and process that likely confer stability advantages, creating a robust protection zone.
- Its strategic value relies on maintaining enforceable claims and monitoring potential overlaps with existing patents.
- Stakeholders should evaluate regional and international patent landscapes for comprehensive market protection.
- The expiration timeline signals potential for generic entry post-closure, emphasizing lifecycle management.
- Ongoing legal and regulatory vigilance is essential to sustain patent validity and commercial advantage.
FAQs
1. What does the scope of the patent CR20130293 cover?
It primarily covers a pharmaceutical composition with specific excipients and a manufacturing method aimed at improving drug stability, with detailed claims on formulations and processes.
2. How does this patent compare to international pharmaceutical patents?
While tailored for Costa Rica, its scope may resemble international patents on stability-enhancing formulations; however, differences in claim language and geographic coverage influence its enforcement.
3. When does the patent CR20130293 expire?
Assuming standard 20-year patent terms from the filing date (~2013), it is expected to expire around 2033, unless early termination or extensions apply.
4. Can generic manufacturers bypass this patent?
Yes, by developing alternative formulations that do not infringe on the claims or by challenging the patent’s validity based on prior art or substantive grounds.
5. What strategic steps should patent holders take?
Enforce the patent locally, pursue regional and international filings, monitor competitor activities, and consider lifecycle extensions or additional patent filings to bolster market position.
Sources:
[1] Costa Rican Industrial Property Office (SNIP).
[2] WIPO Patent Database.
[3] Literature on pharmaceutical formulation patents and regulation.
